T1	Participants 79 94	type 2 diabetes
T2	Participants 293 322	patients with type 2 diabetes
T3	Participants 454 478	type 2 diabetic patients
T4	Participants 617 709	eight patients with type 2 diabetes who were being treated with oral glucose-lowering agents
